Journal of Clinical Oncology
Articles in this Issue
Second opinions and treatment guidance in non- or minimally metastatic testicular cancer: Is ChatGPT 5 non-inferior to expert recommendations?
596 Background: Testicular cancer is rare. Many cases presented to the German online second-opinion platform (eKonsil) inv...
Temporal trends in mortality from bladder cancer with chronic kidney disease in the United States, 1999–2023: A population-based analysis.
649 Background: Bladder cancer frequently coexists with chronic kidney disease (CKD), a comorbidity that may affect treatm...
Serial proteomic characterization of plasma extracellular vesicles (EV) to identify changes that predict outcomes in metastatic castrate-resistant prostate cancer (mCRPC) patients receiving <sup>177</sup> Lu-PSMA-617.
258 Background: Extracellular vesicles (EVs) in plasma offer a minimally invasive window into tumor biology. We hypothesiz...
Network meta-analysis of second- and later-line therapies in advanced renal cell carcinoma: A comparative effectiveness approach.
504 Background: Despite advances with immune checkpoint inhibitors (ICIs) and vascular endothelial growth factor (VEGF)-ta...
Real-world outcomes of systemic therapy in penile cancer: A single-center experience from a tertiary referral hospital in Mexico.
7 Background: Systemic strategies for penile cancer remain poorly defined across heterogeneous stages. We report real-worl...
Divergent biology and outcomes of somatic transformations (SM) in germ cell tumors (GCT).
613 Background: Somatic transformation (SM) of teratoma, defined by dedifferentiation and expansile overgrowth of teratoma...
Response of venous tumor thrombi in renal cell carcinoma to immune checkpoint inhibitor therapy: A multicenter retrospective cohort study.
496 Background: Approximately 10% of patients with renal cell carcinoma (RCC) have an associated venous tumor thrombus (VT...
From innovation to evidence: Trends in AI/ML clinical trials in GU oncology, 2010-2025.
337 Background: Genitourinary (GU) cancers generate complex multimodal data — imaging, pathology, genomics, and clinical v...
Clinical outcomes of neoadjuvant intravesical mitomycin-C therapy administered immediately prior to TURBT in NMIBC: Over three years of follow-up data from a randomized phase II trial.
771 Background: Immediate neoadjuvant intravesical chemotherapy (INAIC) with mitomycin C (MMC), administered before transu...
Addressing barriers to adopting first-line standards of care in la/mUC: A community practice-informed initiative.
660 Background: Rapid advances in 1L therapy for locally advanced/metastatic urothelial carcinoma (la/mUC) have shifted st...
Emotional concerns due to kidney cancer (KC) and disparities in patient support across North America (NA): Results from the International Kidney Cancer Coalition (IKCC) global patient survey (GPS).
490 Background: Patient support services are an important component of care for people with KC that can lead to better out...
Does urinary diversion type influence long-term renal outcomes after radical cystectomy? A multicenter retrospective study.
728 Background: Long-term renal function decline is a known complication following urinary diversion, and its etiology is...
Artificial intelligence (AI)–assisted eligibility screening for prostate cancer clinical trial matching.
405 Background: Clinical trials are critical to advancing prostate cancer treatment, yet patient enrollment remains a majo...
Interim safety and tolerability of TARA-002 in patients with BCG-naïve and unresponsive high-grade non-muscle invasive bladder cancer in ADVANCED-2.
776 Background: There continues to be a significant unmet need for safe, effective, and bladder sparing treatment options...
Efficacy and safety of avelumab + axitinib vs sunitinib in patients (pts) with very favorable-risk advanced renal cell carcinoma (aRCC): Subgroup analysis from the JAVELIN Renal 101 trial.
560 Background: In the JAVELIN Renal 101 phase 3 trial, first-line (1L) treatment with avelumab + axitinib in pts with aRC...
Pattern of disease recurrence and outcomes of localized high-risk renal cell carcinoma (RCC) patients treated with adjuvant (adj) immunotherapy: A single center experience.
510 Background: Standard treatment for high-risk localized RCC is radical or partial nephrectomy followed by adjuvant pemb...
New prostate cancer risk groups by PSMA-PET (PPP3).
20 Background: PSMA-PET usage in prostate cancer patients is growing rapidly. Thus, novel risk group definitions based on...
ARTO trial (NCT03449719): Long-term overall survival analysis from a randomized phase II trial testing the benefit of stereotactic body radiotherapy addition to abiraterone acetate in oligometastatic castrate resistant prostate cancer patients.
151 Background: ARTO (NCT03449719) is a multicentre, randomized phase II trial testing the benefit of stereotactic body ra...
End-of-life treatment patterns in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
92 Background: mCRPC remains the lethal form of metastatic prostate cancer with limited treatment options following diseas...
Efficacy of selective renal tumor embolization combined with axitinib and reduced-dose toripalimab in oligometastatic clear cell renal carcinoma: An updated analysis with patient-derived organoid and immune co-culture insights.
495 Background: Oligometastatic clear cell renal cell carcinoma (ccRCC) presents an opportunity for aggressive local and s...
A phase II study bolstering outcomes by optimizing immunotherapy strategies with evolocumab and nivolumab in patients with metastatic renal cell carcinoma (BOOST-RCC).
TPS581 Background: Metastatic clear cell renal cell carcinoma (mccRCC) progressing on prior immune checkpoint inhibitors (...
Utilization of bone modifying agents in metastatic hormone resistant prostate cancer: A retrospective study of real world patients.
127 Background: Bone metastases affect up to 90 % of patients with metastatic hormone-resistant prostate cancer (mHRPC) an...
Combining PSMA-PET metrics and circulating tumor cell RNA sequencing to predict LuPSMA response.
261 Background: Metastatic castrate-resistant prostate cancer (mCRPC) is a deadly and incurable disease. Targeted radiolig...
The therapeutic efficacy of radical prostatectomy and external beam radiation therapy in patients with histologic variants of prostate cancer.
366 Background: To evaluate the prognostic value of histologic variants of prostate cancer (PCa) in men treated with radic...
Frequency and determinants of reproductive organ involvement in female patients undergoing radical cystectomy for bladder cancer.
699 Background: Traditionally, radical cystectomy (RC) in females includes removal of adjacent reproductive organs (RO) al...